Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy

Phase 4 Unknown 360 enrolled Nanfang Hospital, Southern Medical University Major Science and Technology Special Project of China Eleventh Five-year · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the long-term efficacy and safety of entecavir 1.0 mg/d + adefovir 10 mg/d with entecavir 0.5 mg/d + adefovir 10 mg/d for chronic hepatitis B patients with inadequate response to NUC therapy

Timeline

Start: 2013-03
Primary completion: 2016-06
Completion: —

Publications

Li Y, Pan CQ, Ji S, Yan G, Cheng J, Liu S, Xing H. Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues. Exp Ther Med. 2021 Mar;21(3):216. doi: 10.3892/etm.2021.9648. Epub 2021 Jan 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Adefovir	Unknown	10 mg	Oral
Comparator	Entecavir	Small molecule	0.5 mg	Oral
Comparator	Entecavir	Small molecule	1 mg	Oral

Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy

Summary

Timeline

Publications

Drugs

Indications